NCT03872479 - Single Ascending Dose Study in Participants With LCA10 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

May 23, 2025

Study Completion Date

May 23, 2025

Conditions

Leber Congenital Amaurosis 10Inherited Retinal DystrophiesEye Diseases, HereditaryRetinal DiseaseRetinal DegenerationVision DisordersEye Disorders Congenital

Interventions

DRUG

EDIT-101

Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Trial Locations (5)

19104

University of Pennsylvania, Philadelphia

33136

Bascom Palmer Eye Institute, Miami

48105

W.K. Kellogg Eye Center - University of Michigan, Ann Arbor

97239

Casey Eye Institute - OSHU, Portland

02114

Massachusetts Eye and Ear Infirmary, Boston